Exploring the Tumor and Premetastatic Microenvironment of the Ovary

  title={Exploring the Tumor and Premetastatic Microenvironment of the Ovary},
  author={Curtis W. McCloskey},



International patterns and trends in ovarian cancer incidence, overall and by histologic subtype

Geographic variation in temporal trends of ovarian cancer incidence and differences in the distribution of histologic subtype may be partially explained by reproductive and genetic factors.

Ovarian cancer statistics, 2018

Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection.

Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study

Nulliparity was associated with a substantially greater overall risk than expected from the effect of a single birth, especially for clear cell and endometrioid tumours, perhaps suggesting that infertility is associated with these histotypes.

Inflammation and cancer stem cells.

Concise Review: Stem Cell Antigen‐1: Expression, Function, and Enigma

A review of the plethora of recent findings utilizing Sca‐1 as a parenchymal stem cell marker and detailing its functional role in stem and progenitor cells and also attempts to explain the lingering mysteries surrounding its biochemical function and human ortholog.

Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing

The overall sensitivity of detecting a TP53 mutation based on classification as ‘Low’, ‘Intermediate’ or ‘High’ for p53 IHC was 99%, with a specificity of 75%, and it is suggested p 53 IHC can be used as a surrogate marker of TP53 mutations in HGSOC; however, this will result in misclassification of a proportion of TP 53 wild-type and mutant tumours.

The disparate origins of ovarian cancers: pathogenesis and prevention strategies

Evidence indicates that high-grade serous ovarian carcinomas primarily arise from tissues that are not normally present in the ovary, and histogenetic pathways are informing risk-reduction strategies for the prevention of ovarian and ovary-associated cancers.

Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review

Some of the known molecular mechanisms of chemoresistance that have been exhaustively investigated in chemoresistant ovarian cancer, including drug efflux pump multidrug resistance protein 1 (MDR1), the epithelial–mesenchymal transition, DNA damage and repair capacity are discussed.